Universität zu Köln

Doering, E., Hoenig, M. C., Bischof, G. N., Bohn, K. P., Ellingsen, L. M., van Eimeren, T. and Drzezga, A. (2022). Introducing a gatekeeping system for amyloid status assessment in mild cognitive impairment. Eur. J. Nucl. Med. Mol. Imaging, 49 (13). S. 4478 - 4490. NEW YORK: SPRINGER. ISSN 1619-7089

Full text not available from this repository.

Abstract

Background In patients with mild cognitive impairment (MCI), enhanced cerebral amyloid-beta plaque burden is a high-risk factor to develop dementia with Alzheimer's disease (AD). Not all patients have immediate access to the assessment of amyloid status (A-status) via gold standard methods. It may therefore be of interest to find suitable biomarkers to preselect patients benefitting most from additional workup of the A-status. In this study, we propose a machine learning-based gatekeeping system for the prediction of A-status on the grounds of pre-existing information on APOE-genotype F-18-FDG PET, age, and sex. Methods Three hundred and forty-two MCI patients were used to train different machine learning classifiers to predict A-status majority classes among APOE-epsilon 4 non-carriers (APOE4-nc; majority class: amyloid negative (A beta-)) and carriers (APOE4-c; majority class: amyloid positive (A beta +)) from F-18-FDG-PET, age, and sex. Classifiers were tested on two different datasets. Finally, frequencies of progression to dementia were compared between gold standard and predicted A-status. Results A beta- in APOE4-nc and A beta + in APOE4-c were predicted with a precision of 87% and a recall of 79% and 51%, respectively. Predicted A-status and gold standard A-status were at least equally indicative of risk of progression to dementia. Conclusion We developed an algorithm allowing approximation of A-status in MCI with good reliability using APOE-genotype, F-18-FDG PET, age, and sex information. The algorithm could enable better estimation of individual risk for developing AD based on existing biomarker information, and support efficient selection of patients who would benefit most from further etiological clarification. Further potential utility in clinical routine and clinical trials is discussed.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Doering, E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoenig, M. C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Bischof, G. N. UNSPECIFIED UNSPECIFIED UNSPECIFIED Bohn, K. P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ellingsen, L. M. UNSPECIFIED UNSPECIFIED UNSPECIFIED van Eimeren, T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Drzezga, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-684940
DOI:	10.1007/s00259-022-05879-6
Journal or Publication Title:	Eur. J. Nucl. Med. Mol. Imaging
Volume:	49
Number:	13
Page Range:	S. 4478 - 4490
Date:	2022
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1619-7089
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ALZHEIMERS ASSOCIATION WORKGROUPS; POSITRON-EMISSION-TOMOGRAPHY; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; DISEASE; BIOMARKERS; PET; RECOMMENDATIONS; PREDICTION; CONVERSION Multiple languages Radiology, Nuclear Medicine & Medical Imaging Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/68494